Brivaracetam has received approval as an add-on to primary therapy for partial-onset seizures in patients with epilepsy who are at least 16 years old (http://1.usa.gov/1Tr6bZT).
The drug, marketed as Briviact, has been studied in more than 2400 adults with partial-onset seizures, according to manufacturer UCB, of Smyrna, Georgia (http://bit.ly/1Ucnrmr). In 1 phase 3 trial, the drug was evaluated in 760 patients aged 16 to 80 years whose current medication didn’t control their seizures.
Voelker R. New Option for Treating Epilepsy. JAMA. 2016;315(13):1328. doi:10.1001/jama.2016.2689